Answers are grounded in this paper and cite their sources.
Open science is expected to become an integral component of clinical trials, but, in practice, it is fragmented across various guidelines, laws, funder rules, registry requirements and publishing standards. This fragmentation creates practical challenges for research ethics committees (RECs), which are responsible for protecting participants and reviewing transparency commitments often managed and enforced by other actors such as sponsors, regulators, journals and data access bodies. Focusing on the EU governance context, this multidisciplinary normative analysis examines four transparency practices – open publications, trial registration, results reporting and data sharing – and traces how each has evolved from softer ethical expectations into more institutionalized governance structures. It then analyses what these developments mean for REC review in practice. The paper argues that the mentioned developments do not impact REC work evenly: in some areas, they clarify points of REC involvement, while in others, they mainly reveal the limits of REC influence and the need for clearer responsibility boundaries.
No takes yet. Share an insight, caveat, or question.
Aliukonis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: